Immune-related adverse events with immune checkpoint blockade: a comprehensive review

Abstract Cancer immunotherapy is coming of age; it has prompted a paradigm shift in oncology, in which therapeutic agents are used to target immune cells rather than cancer cells. The first generation of new immunotherapies corresponds to antagonistic antibodies that block specific immune checkpoint...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 2016-02, Vol.54, p.139-148
Hauptverfasser:	Michot, J.M, Bigenwald, C, Champiat, S, Collins, M, Carbonnel, F, Postel-Vinay, S, Berdelou, A, Varga, A, Bahleda, R, Hollebecque, A, Massard, C, Fuerea, A, Ribrag, V, Gazzah, A, Armand, J.P, Amellal, N, Angevin, E, Noel, N, Boutros, C, Mateus, C, Robert, C, Soria, J.C, Marabelle, A, Lambotte, O
Format:	Artikel
Sprache:	eng
Schlagworte:	Abatacept - adverse effects Animals Anti-PD-1 antibody Antibodies - adverse effects Antineoplastic Agents - adverse effects B7-H1 Antigen - antagonists & inhibitors B7-H1 Antigen - immunology B7-H1 Antigen - metabolism CTLA-4 Antigen - antagonists & inhibitors CTLA-4 Antigen - immunology CTLA-4 Antigen - metabolism Cytotoxic T-lymphocyte-associated antigen 4 Drug-Related Side Effects and Adverse Reactions - diagnosis Drug-Related Side Effects and Adverse Reactions - immunology Hematology, Oncology and Palliative Medicine Humans Immune checkpoint blockade Immune-related adverse events Immunotherapy - adverse effects Immunotherapy - methods Molecular Targeted Therapy Neoplasms - drug therapy Neoplasms - immunology Neoplasms - metabolism Neoplasms - pathology Risk Factors Signal Transduction - drug effects Treatment Outcome Tumour neoantigen
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!